Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT500 in Healthy Chinese Adults
NCT06716905Phase 1Completed
- Sponsor
- Xiamen Tebao Biological Engineering Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of azithromycin in Nonalcoholic steatohepatitis (NASH), sponsored by Xiamen Tebao Biological Engineering Co., Ltd. Primary endpoints: Adverse Event and Serious Adverse Event. Started Mar 2025; status: completed.
02
Drugs
azithromycin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06716905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716905.